



Supplemental Figure 2. Expression of a 12-chemokine gene-signature, which has previously been associated with the formation of tertiary lymphoid structures following treatment with different vaccine compositions. Expression data is provided in terms of normalized counts. Bars demonstrate median and interquartile range. N=21. BA=Incomplete Freund's adjuvant; W = weak; P = peptide. \* = <math>P < 0.05</math>, \*\* = <math>P < 0.01</math>, \*\*\* = <math>P < 0.001</math>, \*\*\*\* = <math>P < 0.0001</math>.



Supplemental Figure 3. Expression of a 12-chemokine gene-signature, which has previously been associated with the formation of tertiary lymphoid structures following treatment with different vaccine compositions. Expression data is provided in terms of normalized counts. Bars demonstrate median and interquartile range. N=21. BA=Incomplete Freund's adjuvant; W = weak; P = peptide. \* = <math>P < 0.05</math>, \*\* = <math>P < 0.01</math>, \*\*\* = <math>P < 0.001</math>, \*\*\*\* = <math>P < 0.0001</math>.



Supplemental Figure 4. Expression of a 12-chemokine gene-signature, which has previously been associated with the formation of tertiary lymphoid structures following treatment with different vaccine compositions. Expression data is provided in terms of normalized counts. Bars demonstrate median and interquartile range. N=21. BA=Incomplete Freund's adjuvant; W = weak; P = peptide. \* = <math>P < 0.05</math>, \*\* = <math>P < 0.01</math>, \*\*\* = <math>P < 0.001</math>, \*\*\*\* = <math>P < 0.0001</math>.